SCHEMBL8896348

SCHEMBL8896348

CC(=O)OCCSc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.56
MTNR1B P49286 4/20 0.56
ALDH1A1 P00352 8/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.50
MAPT P10636 3/20 0.50
RECQL P46063 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C19 P33261 2/20 0.50
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP2C9 P11712 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
FFAR1 O14842 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3920674 0.87 PTGS2 (0.62) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL11299567 0.87 ELANE (0.51) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL9427645 0.84 ALDH1A1 (0.56) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL10986628 0.84 MTNR1A (0.56) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL12317734 0.84 ALDH1A1 (0.46) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL1710082 0.83 ALDH1A1 (0.49) ALDH1A1MAPK1SMN1; SMN2MAPTCYP1A2
SCHEMBL27858437 0.83 HSP90AA1 (0.45) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL11846875 0.82 ALDH1A1 (0.54) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL6248478 0.82 ALDH1A1 (0.52) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2
SCHEMBL9427635 0.82 ALDH1A1 (0.54) MTNR1AMTNR1BALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
CN-113329663-A Cosmetic unit 松下知识产权经营株式会社 2021-08-31 CN disclosed
WO-2021039783-A1 CURABLE INK COMPOSITION, CURED MATERIAL AND NANOCOMPOSITE 東京応化工業株式会社 2021-03-04 WO disclosed
US-20200371435-A1 BLUE CURABLE RESIN COMPOSITION, BLUE COLOR FILTER, AND DISPLAY DEVICE INCLUDING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-11-26 US disclosed
US-9682911-B2 Method for producing α-halogenoacetophenon compound, and α-bromoacetophenon compound FUJIFILM CORPORATION (JP) 2017-06-20 US disclosed
US-9682911-B2 Method for producing α-halogenoacetophenon compound, and α-bromoacetophenon compound FUJIFILM CORPORATION (JP) 2017-06-20 US disclosed
EP-3053908-A1 METHOD FOR PRODUCING alpha-HALOGENOACETOPHENON COMPOUND, AND alpha-BROMOACETOPHENON COMPOUND FUJIFILM Corporation (JP) 2016-08-10 EP disclosed
US-20160200654-A1 METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND FUJIFILM CORPORATION (JP) 2016-07-14 US disclosed
US-20160200654-A1 METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND FUJIFILM CORPORATION (JP) 2016-07-14 US disclosed
US-5670563-A ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND CIBA-SPECIALTY CHEMICALS CORPORATION (US) 1997-09-23 US disclosed
EP-0767791-A1 ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY MERCK & CO. INC. (US) 1997-04-16 EP disclosed
US-5550233-A AUTOIMMUNE DISEASES; PREVENTION OF TRANSPLANT REJECTION MERCK & CO., INC. (US) 1996-08-27 US disclosed
WO-1995035299-A1 ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY MERCK & CO., INC. (US) 1995-12-28 WO disclosed
US-4036984-A PHENOXYETHYL FATTY ACID ESTER NISSAN CHEMICAL INDUSTRIES, LTD. (JA) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200654-A1 METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND CYP2B6, CYP2A6, CA6 MTNR1A 4054/4885MTNR1B 3838/4885ALDH1A1 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.